Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response

References

• SainiKSAzimHAJrMetzger-FilhoOBeyond trastuzumab: new treatment options for HER2-positive breast cancerBreast201120Suppl 3S20S27
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet2012379981663364022257673
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer20055534135415864276
   PubMed Web of Science ®Google Scholar
• BunneyTDKatanMPhosphoinositide signalling in cancer: beyond PI3K and PTENNat Rev Cancer201010534235220414202
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• WangLZhangQZhangJPI3K pathway activation results in low efficacy of both trastuzumab and lapatinibBMC Cancer20111124821676217
   PubMed Web of Science ®Google Scholar
• JensenJDKnoopALaenkholmAVPIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumabAnn Oncol20122382034204222172323
   PubMed Web of Science ®Google Scholar
• PuglisiFMinisiniAMDe AngelisCArpinoGOvercoming treatment resistance in HER2-positive breast cancer: potential strategiesDrugs20127291175119322686613
   PubMed Web of Science ®Google Scholar
• RazisEBobosMKotoulaVEvaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancerBreast Cancer Res Treat2011128244745621594665
   PubMed Web of Science ®Google Scholar
• ArribasJBaselgaJPedersenKParra-PalauJLp95HER2 and breast cancerCancer Re201171515151519
   Web of Science ®Google Scholar
• RossJSGayLMWangKNonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for anti-HER2 targeted therapiesCancer2016122172654266227284958
   PubMed Web of Science ®Google Scholar
• GarnettMJEdelmanEJHeidornSJSystematic identification of genomic markers of drug sensitivity in cancer cellsNature2012483739157057522460902
   PubMed Web of Science ®Google Scholar
• BarretinaJCaponigroGStranskyNThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature2012483739160330722460905
   PubMed Web of Science ®Google Scholar
• WangYCMorrisonGGillihanRDifferent mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers: role of estrogen receptor and HER2 reactivationBreast Cancer Res2011136R12122123186
   PubMed Web of Science ®Google Scholar
• KurebayashiJOtsukiTTangCKIsolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6Br J Cancer1999795–670771710070858
   PubMed Web of Science ®Google Scholar
• TannerMKapanenAJunttilaTCharacterization of a novel cell line established from a patient with Herceptin-resistant breast cancerMol Cancer Ther20043121585159215634652
   PubMed Web of Science ®Google Scholar
• AirdKMDingXBarasATrastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expressionMol Cancer Ther200871384718202008
   PubMed Web of Science ®Google Scholar
• GazdarAFKurvariVVirmaniACharacterization of paired tumor and non-tumor cell lines established from patients with breast cancerInt J Cancer19987867667749833771
   PubMed Web of Science ®Google Scholar
• SamuelsYVelculescuVEOncogenic mutations of PIK3CA in human cancersCell Cycle20043101221122415467468
   PubMed Web of Science ®Google Scholar
• Applied BiosystemsDNA Sequencing by Capillary Electrophoresis Chemistry Guide2nd edFoster City (CA)Applied Biosystems2009
   Google Scholar
• SahlbergKKHongistoVEdgrenHThe HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cellsMol Oncol20137339240123253899
   PubMed Web of Science ®Google Scholar
• R Core TeamThe R project for statistical computing2014 Available from: https://www.r-project.orgAccessed September 21, 2016
   Google Scholar
• NilsenGLiestølKVan LooPCopynumber: efficient algorithms for single- and multi-track copy number segmentationBMC Genomics20121359123442169
   PubMed Web of Science ®Google Scholar
• RussnesHGVollanHKLingjærdeOCGenomic architecture characterizes tumor progression paths and fate in breast cancer patientsSci Transl Med201023838ra47
   Web of Science ®Google Scholar
• IrizarryRABolstadBMCollinFCopeLMHobbsBSpeedTPSummaries of Affymetrix GeneChip probe level dataNucleic Acids Res2003314e1512582260
   PubMed Web of Science ®Google Scholar
• DaiMWangPBoydADEvolving gene/transcript definitions significantly alter the interpretation of GeneChip dataNucleic Acids Res20053320e17516284200
   PubMed Web of Science ®Google Scholar
• WarnesGRBolkerBBonebakkerLGplots: various R programming tools for plotting data2012 Available from: http://cran.r-project.org/package=gplotsAccessed September 21, 2016
   Google Scholar
• KanehisaMGotoSKEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Res2000281273010592173
   PubMed Web of Science ®Google Scholar
• KanehisaMGotoSSatoYFurumichiMTanabeMKEGG for integration and interpretation of large-scale molecular data setsNucleic Acids Res201240D1D109D11422080510
   PubMed Web of Science ®Google Scholar
• DimmerECHuntleyRPAlam-FaruqueYThe UniProt-GO Annotation database in 2011Nucleic Acids Res201240Database issueD56557022123736
   PubMed Web of Science ®Google Scholar
• NishimuraDBioCartaBiotech Softw Internet Rep2001234
   Google Scholar
• KelderTvan IerselMPHanspersKWikiPathways: building research communities on biological pathwaysNucleic Acids Research201140Database issueD1301D130722096230
   PubMed Web of Science ®Google Scholar
• ZouHHastieTRegularization and variable selection via the elastic netJ R Stat Soc Series B Stat Methodol2005672301320
   Web of Science ®Google Scholar
• ZouHHastieTTibshiraniRSparse principal component analysisJ Comput Graph Stat2006152265286
   Web of Science ®Google Scholar
• WilsonJRBatemanACHansonHA novel HER2-positive breast cancer phenotype arising from germline TP53 mutationsJ Med Genet2010471177177420805372
   PubMed Web of Science ®Google Scholar
• KöninkiKBarokMTannerMMultiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cellsCancer Lett2010294221121920193978
   PubMed Web of Science ®Google Scholar
• MyhreSLingjærdeOCHennessyBTInfluence of DNA copy number and mRNA levels on the expression of breast cancer related proteinsMol Oncol20137370471823562353
   PubMed Web of Science ®Google Scholar
• VranicSGatalicaZWangZYUpdate on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studiesOncol Lett2011261131113722121396
   PubMed Web of Science ®Google Scholar
• VranicSMarchioCCastellanoIImmunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breastHum Pathol20154691350135926208846
   PubMed Web of Science ®Google Scholar
• PuglisiFFontanellaCAmorosoVCurrent challenges in HER2-positive breast cancerCrit Rev Oncol Hematol20169821122126638862
   PubMed Web of Science ®Google Scholar
• PicklMRiesCHComparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumabOncogene200828346146818978815
   PubMed Web of Science ®Google Scholar
• XiaWHusainILiuLLapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersCancer Res20076731170117517283152
   PubMed Web of Science ®Google Scholar
• BonottoMGerratanaLIaconoDTreatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines?Oncologist201520771972426018662
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• ArteagaCLSliwkowskiMXOsborneCKPerezEAPuglisiFGianniLTreatment of HER2-positive breast cancer: current status and future perspectivesNat Rev Clin Oncol2012911632
   Web of Science ®Google Scholar
• WangQDingHLiuBAddition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumorsInt J Oncol20144441277128324452693
   PubMed Web of Science ®Google Scholar
• TianSSimonIMorenoVA combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment predictionGut201362454054922798500
   PubMed Web of Science ®Google Scholar
• HuangJWangSLyuHThe anti-ErbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cellsMol Cancer201312113424215614
   PubMed Web of Science ®Google Scholar
• KirouacDCDuJYLahdenrantaJComputational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitorsSci Signal20136288ra6823943608
   PubMed Web of Science ®Google Scholar
• GarrettJTSuttonCRKurupiRCombination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancersCancer Res201373196013602323918797
   PubMed Web of Science ®Google Scholar
• JiaYZhangYQiaoCIGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer modelBiochem Biophys Res Commun2013436474074523792093
   PubMed Web of Science ®Google Scholar
• SchneiderMRWolfEThe epidermal growth factor receptor ligands at a glanceJ Cell Physiol2009218346046619006176
   PubMed Web of Science ®Google Scholar
• ArteagaCLEngelmanJAERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeuticsCancer Cell201425328230324651011
   PubMed Web of Science ®Google Scholar